Pulse Biosciences, Inc. (PLSE) Appoints Laureen DeBuono to Its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors
October 5, 2021 8:00 AM EDTHAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation (NPS) technology, today announced the appointment of Laureen DeBuono to its Board of Directors. Concurrent to Ms. DeBuonos appointment, Kenneth Clark has resigned from the Board of Directors.
We are delighted and honored to welcome Laureen to the Pulse Biosciences Board, said Robert Duggan, Chairman of the Pulse Biosciences Board of Directors. Laureen is an accomplished executive with a track record of driving growth and creating shareholder value through operational,... More
